Natco Pharma Ltd.
NSE: NATCOPHARM | BSE: 524816
₹891.50
₹-1.90
(-0.21%)
As on 08-Jun-2026 09:39IST
Market cap
₹16,006 Cr
Revenue (TTM)
₹4,078 Cr
P/E Ratio
11.3
P/B Ratio
1.7
Div. Yield
0.6 %
Quality Score
10/10
Growth Score
7/10
Valuation Score
7/10
Momentum Score
8/10
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
₹1,419 Cr
-
ROE
28 %
-
ROCE
32.8 %
-
Industry P/E
44.87
-
EV/EBITDA
8.7
-
Debt to Equity
0
-
Book Value
₹514.8
-
EPS
₹79.2
-
Face value
2
-
Shares outstanding
179,109,870
10 Years Aggregate
CFO
₹6,110.50 Cr
EBITDA
₹8,979.00 Cr
Net Profit
₹7,033.60 Cr
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Natco Pharma
| -1.3 | -22.8 | -12.6 | 3.9 | 12.7 | -3.0 | 5.4 |
|
BSE Healthcare
| 8.2 | 1.3 | 7.8 | 8.7 | 24.3 | 13.6 | 12.1 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Natco Pharma
| -35.4 | 69.5 | 44.5 | -37.9 | -6.5 | 55.6 | -14.5 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Natco Pharma
|
891.5 | 16,006.2 | 4,078.3 | 1,371.9 | 30.2 | 15.9 | 11.3 | 1.7 |
| 3,391.6 | 27,250.0 | 1,339.4 | 356.4 | 33.2 | 23.2 | 76.5 | 16.5 | |
| 736.1 | 14,485.7 | 7,344.9 | 670.6 | 10.9 | 13.7 | 21.5 | 2.6 | |
| 424.6 | 16,486.7 | 2,268.6 | 150.1 | 10.6 | 5.4 | 92 | 4.2 | |
| 786.0 | 19,566.0 | 5,365.6 | 595.0 | 16.6 | 13.3 | 32.9 | 3.8 | |
| 961.8 | 15,505.2 | 8,279.6 | 397.8 | 9.9 | 6.4 | 38.9 | 2.2 | |
| 1,740.9 | 20,522.2 | 1,421.6 | -73.8 | 1.8 | -1.1 | -- | 3.5 | |
| 165.2 | 22,200.2 | 8,869.1 | -383.1 | 1.0 | -4.2 | -- | 2.7 | |
| 448.8 | 17,527.3 | 3,738.7 | 316.7 | 12.5 | 7.5 | 55.3 | 3.6 | |
| 1,937.5 | 31,200.9 | 3,373.0 | 199.0 | 12.6 | 5.9 | 146.5 | 6.3 |
Shareholding Pattern
View DetailsNews & Analysis
All News
From past growth to future prosperity
6 min read•By Rajan Gulati
Three mid caps that are up for easy grabs
5 min read•By Yash Rohra
4 min read•By Rajan Gulati
1 min read•By Research Desk
About Natco Pharma
NATCO Pharma Limited, a pharmaceutical company, engages in the developing, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. It... offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. The company offers orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, it provides cardiology and diabetology products for the treatment of hypertension, stable angina, and CHF. Further, the company offers agro chemicals and biological pest management solutions for management of insects, diseases, and weeds across a range of crops. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India. Read more
-
Incorporated
1981
-
Chairman
V C Nannapaneni
-
Managing Director
V C Nannapaneni
-
Group
Natco
-
Headquarters
Hyderabad, Telangana
-
Website
Looking for more details about Natco Pharma Ltd.’s IPO? Explore our IPO Details page.
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
Quarterly Updates
Annual Reports
FAQs for Natco Pharma
What is the current share price of Natco Pharma Ltd Today?
The share price of Natco Pharma Ltd is ₹891.50 (NSE) and ₹887.75 (BSE) as of 08-Jun-2026 09:39 IST. Natco Pharma Ltd has given a return of 12.72% in the last 3 years.
What is the current PB & PE ratio of Natco Pharma Ltd?
The P/E ratio of Natco Pharma Ltd is 11.28 times as on 05-Jun-2026, a 75 discount to its peers’ median range of 44.87 times.
The P/B ratio of Natco Pharma Ltd is 1.74 times as on 05-Jun-2026, a 58 discount to its peers’ median range of 4.10 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
7.57
|
1.88
|
|
2024
|
12.27
|
2.91
|
|
2023
|
14.38
|
2.11
|
|
2022
|
81.30
|
3.24
|
|
2021
|
34.16
|
3.67
|
What is the 52 Week High and Low of Natco Pharma Ltd?
The 52-week high and low of Natco Pharma Ltd are Rs 1,226.80 and Rs 789.00 as of 08-Jun-2026.
What is the market cap of Natco Pharma Ltd?
Natco Pharma Ltd has a market capitalisation of ₹ 16,006 Cr as on 05-Jun-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Natco Pharma Ltd?
Before investing in Natco Pharma Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.